Search clinical trials for: Lumasiran
Total 10 results
-
Charite University, Berlin, GermanyAlnylam PharmaceuticalsNot yet recruitingCardiovascular Disease | Cardiovascular Risk Factor | Haemodialysis | Chronic Kidney Disease Requiring Chronic Dialysis | Hyperoxalemia
-
Alnylam PharmaceuticalsCompletedPrimary Hyperoxaluria | PH1 | RNAi Therapeutic | siRNA | AGTFrance, United Kingdom, Netherlands, Israel, Germany
-
Alnylam PharmaceuticalsCompletedPrimary Hyperoxaluria Type 1 (PH1)France, United Kingdom, Netherlands, Israel, Germany
-
Alnylam PharmaceuticalsCompletedPrimary Hyperoxaluria Type 1 (PH1)United States, France, United Kingdom, Switzerland, Netherlands, Israel, Germany, United Arab Emirates
-
LumaMedUniversity of Wisconsin, MadisonUnknownBreast CancerUnited States
-
Alnylam PharmaceuticalsTerminatedRecurrent Calcium Oxalate Kidney Stone Disease | Elevated Urinary Oxalate LevelsUnited States, Italy, Spain, Belgium, Switzerland, United Kingdom
-
Alnylam PharmaceuticalsActive, not recruitingPrimary Hyperoxaluria Type 1 (PH1) | Primary HyperoxaluriaUnited States, France, United Kingdom, Israel, Germany
-
Alnylam PharmaceuticalsApproved for marketingPrimary HyperoxaluriaBelgium
-
Alnylam PharmaceuticalsActive, not recruitingPrimary Hyperoxaluria Type 1 | Primary HyperoxaluriaUnited States, Italy, France, Lebanon, Belgium, Netherlands, Israel, United Arab Emirates, Australia, Jordan, Turkey
-
Genzyme, a Sanofi CompanyWithdrawnEndometrial CancerUnited States